Celldex Therapeutics, Inc. (CLDX) Position Increased by TSP Capital Management Group LLC

TSP Capital Management Group LLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 12.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,436,957 shares of the biopharmaceutical company’s stock after purchasing an additional 158,900 shares during the quarter. Celldex Therapeutics accounts for approximately 1.6% of TSP Capital Management Group LLC’s holdings, making the stock its 26th biggest holding. TSP Capital Management Group LLC owned approximately 1.00% of Celldex Therapeutics worth $3,348,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Virtus Fund Advisers LLC purchased a new position in shares of Celldex Therapeutics during the fourth quarter worth approximately $338,000. BlackRock Inc. boosted its stake in Celldex Therapeutics by 2.9% in the fourth quarter. BlackRock Inc. now owns 9,930,701 shares of the biopharmaceutical company’s stock valued at $28,203,000 after acquiring an additional 279,287 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Celldex Therapeutics by 15.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 661,295 shares of the biopharmaceutical company’s stock valued at $1,879,000 after acquiring an additional 90,188 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in Celldex Therapeutics by 325.0% in the fourth quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 33,077 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Celldex Therapeutics in the fourth quarter valued at approximately $800,000. 54.82% of the stock is currently owned by institutional investors.

CLDX has been the subject of several recent analyst reports. HC Wainwright set a $10.00 target price on shares of Celldex Therapeutics and gave the company a “buy” rating in a research note on Friday, February 9th. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, March 7th. BidaskClub upgraded shares of Celldex Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Cowen restated a “hold” rating on shares of Celldex Therapeutics in a research note on Thursday, May 10th. Finally, Leerink Swann reiterated a “market perform” rating and set a $3.00 price objective (down from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. Celldex Therapeutics presently has a consensus rating of “Hold” and an average price target of $4.35.

Shares of NASDAQ:CLDX traded down $0.01 on Wednesday, hitting $0.69. 7,111 shares of the company were exchanged, compared to its average volume of 2,331,446. Celldex Therapeutics, Inc. has a 1-year low of $0.69 and a 1-year high of $0.71. The company has a market capitalization of $103.24 million, a P/E ratio of -0.88 and a beta of 2.52.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.08. The business had revenue of $3.50 million during the quarter, compared to the consensus estimate of $1.49 million. Celldex Therapeutics had a negative net margin of 1,157.96% and a negative return on equity of 47.36%. The business’s revenue for the quarter was up 87.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.30) earnings per share. research analysts forecast that Celldex Therapeutics, Inc. will post -0.75 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply